Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway.
Animals
Cells, Cultured
Coinfection
/ virology
DEAD Box Protein 58
/ metabolism
DEAD-box RNA Helicases
/ metabolism
Down-Regulation
Hepatitis B virus
/ physiology
Hepatitis C
/ virology
Hepatitis C, Chronic
/ virology
Hepatocytes
/ virology
Humans
Liver
/ metabolism
Mice
Receptors, Immunologic
Signal Transduction
Virus Replication
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
22 01 2020
22 01 2020
Historique:
received:
16
07
2019
accepted:
03
01
2020
entrez:
24
1
2020
pubmed:
24
1
2020
medline:
2
12
2020
Statut:
epublish
Résumé
Mechanisms of hepatitis B virus (HBV) reactivation after hepatitis C virus (HCV) elimination by direct-acting antiviral (DAA) treatment in HBV/HCV-co-infected patients remain unclear. We examined RIG-I-like helicase (RLH) pathway activation by HBV mono-infection, HCV mono-infection or HBV/HCV co-infection and interference between HBV and HCV in primary human hepatocytes. Interference between HBV and HCV and HBV reactivation after DAA treatment in humanized-liver mice were assessed. HCV infection activated RLH pathway, as evidenced by RIG-I, ISG15 and ISG56 expression induction; HBV caused only RIG-I induction in vitro. RLH activation was also found in HBV/HCV-co-infected cells, and HBV replication were suppressed in HBV/HCV-co-infected than in HBV-mono-infected cells. siRNA-mediated double knockdown of ISG15 and ISG56 increased HBV replication in HBV/HCV-co-infected cells. HCV infection activated RLH pathway and suppressed HBV replication in humanized-liver mice. Subsequent elimination of HCV by DAA administration downregulated RLH pathway and upregulated HBV replication in mice. RLH pathway was activated in livers of chronic hepatitis C patients compared to those of chronic hepatitis B or non-B, non-C patients. The RLH pathway activation was downregulated by HCV elimination. In conclusion, HCV infection activated RLH pathway and suppressed HBV replication in human hepatocytes. HCV elimination upregulated HBV replication, probably through RLH pathway downregulation.
Identifiants
pubmed: 31969598
doi: 10.1038/s41598-020-57603-9
pii: 10.1038/s41598-020-57603-9
pmc: PMC6976581
doi:
Substances chimiques
Receptors, Immunologic
0
RIGI protein, human
EC 3.6.1.-
DEAD Box Protein 58
EC 3.6.4.13
DEAD-box RNA Helicases
EC 3.6.4.13
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
941Références
Liu, C. J., Liou, J. M., Chen, D. S. & Chen, P. J. Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. J. Formos. Med. Assoc. 104, 783–791 (2005).
pubmed: 16496056
Chen, D. S. et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J. Infect. Dis. 162, 817–822 (1990).
doi: 10.1093/infdis/162.4.817
Liu, C. J. et al. Clinical aspects and outcomes of volunteer blood donors testing positive for hepatitis-C virus infection in Taiwan: a prospective study. Liver Int. 23, 148–155 (2003).
doi: 10.1034/j.1600-0676.2003.00820.x
Liu, C. J. & Chen, P. J. Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection. World J. Gastroenterol. 20, 2955–2961, https://doi.org/10.3748/wjg.v20.i11.2955 (2014).
doi: 10.3748/wjg.v20.i11.2955
pubmed: 24659886
pmcid: 3961993
Pallás, J. R., Fariñas-Alvarez, C., Prieto, D. & Delgado-Rodríguez, M. Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users. Eur. J. Epidemiol. 15, 699–704 (1999).
doi: 10.1023/A:1007619614350
Chu, C. M., Yeh, C. T. & Liaw, Y. F. Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C virus infection. J. Clin. Microbiol. 36, 2084–2086 (1998).
doi: 10.1128/JCM.36.7.2084-2086.1998
Jardi, R. et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 34, 404–410, https://doi.org/10.1053/jhep.2001.26511 (2001).
doi: 10.1053/jhep.2001.26511
pubmed: 11481626
Jiang, X. W., Ye, J. Z., Li, Y. T. & Li, L. J. Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis. World J. Gastroenterol. 24, 3181–3191, https://doi.org/10.3748/wjg.v24.i28.3181 (2018).
doi: 10.3748/wjg.v24.i28.3181
pubmed: 30065564
pmcid: 6064961
Mücke, M. M. et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 3, 172–180, https://doi.org/10.1016/S2468-1253(18)30002-5 (2018).
doi: 10.1016/S2468-1253(18)30002-5
pubmed: 29371017
Doi, A. et al. Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: Analysis of a Japanese prospective cohort. Hepatol. Res. 47, 1438–1444, https://doi.org/10.1111/hepr.12919 (2017).
doi: 10.1111/hepr.12919
pubmed: 28585404
Kawagishi, N. et al. Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection. J. Hepatol. 67, 1106–1108, https://doi.org/10.1016/j.jhep.2017.04.008 (2017).
doi: 10.1016/j.jhep.2017.04.008
pubmed: 28438688
Sato, K. et al. Spontaneous remission of hepatitis B virus reactivation during direct-acting antiviral agent-based therapy for chronic hepatitis C. Hepatol. Res. 47, 1346–1353, https://doi.org/10.1111/hepr.12905 (2017).
doi: 10.1111/hepr.12905
pubmed: 28422376
Collins, J. M. et al. Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir. Clin. Infect. Dis. 61, 1304–1306, https://doi.org/10.1093/cid/civ474 (2015).
doi: 10.1093/cid/civ474
pubmed: 26082511
Takayama, H., Sato, T., Ikeda, F. & Fujiki, S. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatol. Res. 46, 489–491, https://doi.org/10.1111/hepr.12578 (2016).
doi: 10.1111/hepr.12578
pubmed: 26297529
Di Bisceglie, A. M. et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 61, 703–711, https://doi.org/10.1002/hep.27609 (2015).
doi: 10.1002/hep.27609
pubmed: 25412906
pmcid: 5497492
Nakabori, T. et al. Sodium taurocholate cotransporting polypeptide inhibition efficiently blocks hepatitis B virus spread in mice with a humanized liver. Sci. Rep. 6, 27782, https://doi.org/10.1038/srep27782 (2016).
doi: 10.1038/srep27782
pubmed: 27278060
pmcid: 4899802
Loo, Y. M. & Gale, M. Immune signaling by RIG-I-like receptors. Immunity 34, 680–692, https://doi.org/10.1016/j.immuni.2011.05.003 (2011).
doi: 10.1016/j.immuni.2011.05.003
pubmed: 21616437
pmcid: 3177755
Arnaud, N. et al. Hepatitis C virus reveals a novel early control in acute immune response. PLoS Pathog. 7, e1002289, https://doi.org/10.1371/journal.ppat.1002289 (2011).
doi: 10.1371/journal.ppat.1002289
pubmed: 22022264
pmcid: 3192838
Lenschow, D. J. et al. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc. Natl Acad. Sci. USA 104, 1371–1376, https://doi.org/10.1073/pnas.0607038104 (2007).
doi: 10.1073/pnas.0607038104
pubmed: 17227866
Pei, R. et al. Interferon-induced proteins with tetratricopeptide repeats 1 and 2 are cellular factors that limit hepatitis B virus replication. J. Innate Immun. 6, 182–191, https://doi.org/10.1159/000353220 (2014).
doi: 10.1159/000353220
pubmed: 23867918
Dong, H. J. et al. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis. J. Clin. Virol. 57, 209–214, https://doi.org/10.1016/j.jcv.2013.03.010 (2013).
doi: 10.1016/j.jcv.2013.03.010
pubmed: 23562041
Kusumoto, S. et al. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood 133, 137–146, https://doi.org/10.1182/blood-2018-04-848044 (2019).
doi: 10.1182/blood-2018-04-848044
pubmed: 30341058
pmcid: 6337873
Choi, S. W. & Reddy, P. Current and emerging strategies for the prevention of graft-versus-host disease. Nat. Rev. Clin. Oncol. 11, 536–547, https://doi.org/10.1038/nrclinonc.2014.102 (2014).
doi: 10.1038/nrclinonc.2014.102
pubmed: 24958183
pmcid: 4151470
Hikita, H. et al. Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis. Cancer Prev. Res. (Phila.) 8, 693–701, https://doi.org/10.1158/1940-6207.CAPR-15-0022-T (2015).
doi: 10.1158/1940-6207.CAPR-15-0022-T
Sells, M. A., Chen, M. L. & Acs, G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl Acad. Sci. USA 84, 1005–1009 (1987).
doi: 10.1073/pnas.84.4.1005
Wakita, T. Isolation of JFH-1 strain and development of an HCV infection system. Methods Mol. Biol. 510, 305–327, https://doi.org/10.1007/978-1-59745-394-3_23 (2009).
doi: 10.1007/978-1-59745-394-3_23
pubmed: 19009271
Hasegawa, M. et al. The reconstituted ‘humanized liver’ in TK-NOG mice is mature and functional. Biochem. Biophys. Res. Commun. 405, 405–410, https://doi.org/10.1016/j.bbrc.2011.01.042 (2011).
doi: 10.1016/j.bbrc.2011.01.042
pubmed: 21238430
pmcid: 3648850
Doi, A. et al. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice. J. Gastroenterol. 54, 449–458, https://doi.org/10.1007/s00535-018-01541-x (2019).
doi: 10.1007/s00535-018-01541-x
pubmed: 30684016
Matsunaga, S. et al. Wheat germ cell-free system-based production of hemagglutinin-neuraminidase glycoprotein of human parainfluenza virus type 3 for generation and characterization of monoclonal antibody. Front. Microbiol. 5, 208, https://doi.org/10.3389/fmicb.2014.00208 (2014).
doi: 10.3389/fmicb.2014.00208
pubmed: 24860558
pmcid: 4026691
Okuyama-Dobashi, K. et al. Hepatitis B virus efficiently infects non-adherent hepatoma cells via human sodium taurocholate cotransporting polypeptide. Sci. Rep. 5, 17047, https://doi.org/10.1038/srep17047 (2015).
doi: 10.1038/srep17047
pubmed: 26592202
pmcid: 4655410